108 related articles for article (PubMed ID: 11216808)
21. Failure of cryopreserved homograft valved conduits in the pulmonary circulation.
Cleveland DC; Williams WG; Razzouk AJ; Trusler GA; Rebeyka IM; Duffy L; Kan Z; Coles JG; Freedom RM
Circulation; 1992 Nov; 86(5 Suppl):II150-3. PubMed ID: 1423992
[TBL] [Abstract][Full Text] [Related]
22. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
23. Right ventricle-to-pulmonary artery conduit longevity: is it related to allograft size?
Askovich B; Hawkins JA; Sower CT; Minich LL; Tani LY; Stoddard G; Puchalski MD
Ann Thorac Surg; 2007 Sep; 84(3):907-11; discussion 911-2. PubMed ID: 17720398
[TBL] [Abstract][Full Text] [Related]
24. Circulating donor-specific cytotoxic T lymphocytes with high avidity for donor human leukocyte antigens in pediatric and adult cardiac allograft valved conduit recipients.
Oei FB; Welters MJ; Knoop CJ; Vaessen LM; Stegmann AP; Weimar W; Bogers AJ
Eur J Cardiothorac Surg; 2000 Oct; 18(4):466-72. PubMed ID: 11024386
[TBL] [Abstract][Full Text] [Related]
25. Six-year monitoring of the donor-specific immune response to cryopreserved aortic allograft valves: implications with valve dysfunction.
Pompilio G; Polvani G; Piccolo G; Guarino A; Nocco A; Innocente A; Porqueddu M; Dainese L; Veglia F; Sala A; Biglioli P
Ann Thorac Surg; 2004 Aug; 78(2):557-63. PubMed ID: 15276519
[TBL] [Abstract][Full Text] [Related]
26. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation.
da Costa FD; Dohmen PM; Duarte D; von Glenn C; Lopes SV; Filho HH; da Costa MB; Konertz W
Eur J Cardiothorac Surg; 2005 Apr; 27(4):572-8. PubMed ID: 15784353
[TBL] [Abstract][Full Text] [Related]
27. Does histocompatibility affect homograft valve function after the Ross procedure?
Bechtel JF; Bartels C; Schmidtke C; Skibba W; Müller-Steinhardt M; Klüter H; Sievers HH
Circulation; 2001 Sep; 104(12 Suppl 1):I25-8. PubMed ID: 11568025
[TBL] [Abstract][Full Text] [Related]
28. Accelerated degeneration of allografts in the first two years of life.
Yankah AC; Alexi-Meskhishvili V; Weng Y; Schorn K; Lange PE; Hetzer R
Ann Thorac Surg; 1995 Aug; 60(2 Suppl):S71-6; discussion 576-7. PubMed ID: 7646214
[TBL] [Abstract][Full Text] [Related]
29. Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts.
Homann M; Haehnel JC; Mendler N; Paek SU; Holper K; Meisner H; Lange R
Eur J Cardiothorac Surg; 2000 Jun; 17(6):624-30. PubMed ID: 10856850
[TBL] [Abstract][Full Text] [Related]
30. Degeneration of aortic valve allografts in young recipients.
Clarke DR; Campbell DN; Hayward AR; Bishop DA
J Thorac Cardiovasc Surg; 1993 May; 105(5):934-41; discussion 941-2. PubMed ID: 8487572
[TBL] [Abstract][Full Text] [Related]
31. Decellularized versus standard cryopreserved valve allografts for right ventricular outflow tract reconstruction: a single-institution comparison.
Ruzmetov M; Shah JJ; Geiss DM; Fortuna RS
J Thorac Cardiovasc Surg; 2012 Mar; 143(3):543-9. PubMed ID: 22340029
[TBL] [Abstract][Full Text] [Related]
32. Conduit reconstruction of the right ventricular outflow tract. Lessons learned in a twelve-year experience.
Albert JD; Bishop DA; Fullerton DA; Campbell DN; Clarke DR
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):228-35; discussion 235-6. PubMed ID: 8341063
[TBL] [Abstract][Full Text] [Related]
33. Immune response to allograft implantation in children with congenital heart defects.
Arrington CB; Shaddy RE
Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):695-701. PubMed ID: 17081091
[TBL] [Abstract][Full Text] [Related]
34. Superior durability of SynerGraft pulmonary allografts compared with standard cryopreserved allografts.
Tavakkol Z; Gelehrter S; Goldberg CS; Bove EL; Devaney EJ; Ohye RG
Ann Thorac Surg; 2005 Nov; 80(5):1610-4. PubMed ID: 16242425
[TBL] [Abstract][Full Text] [Related]
35. Midterm results with cryopreserved allograft valved conduits from the right ventricle to the pulmonary arteries.
Hawkins JA; Bailey WW; Dillon T; Schwartz DC
J Thorac Cardiovasc Surg; 1992 Oct; 104(4):910-6. PubMed ID: 1405689
[TBL] [Abstract][Full Text] [Related]
36. Intermediate-term fate of cryopreserved allograft and xenograft valved conduits.
Kirklin JW; Blackstone EH; Maehara T; Pacifico AD; Kirklin JK; Pollock S; Stewart RW
Ann Thorac Surg; 1987 Dec; 44(6):598-606. PubMed ID: 3689046
[TBL] [Abstract][Full Text] [Related]
37. Human leukocyte antigen mismatch and other factors affecting cryopreserved allograft valve function.
Yap CH; Skillington PD; Matalanis G; Davis BB; Tait BD; Hudson F; Ireland L; Nixon I; Yii M
Heart Surg Forum; 2008; 11(1):E42-5. PubMed ID: 18270140
[TBL] [Abstract][Full Text] [Related]
38. Pathological considerations in cryopreserved allograft heart valves.
Schoen FJ; Mitchell RN; Jonas RA
J Heart Valve Dis; 1995 Jul; 4 Suppl 1():S72-5; discussion S75-6. PubMed ID: 8581216
[TBL] [Abstract][Full Text] [Related]
39. The Ross procedure in children and young adults with congenital aortic valve disease.
Walters HL; Lobdell KW; Tantengco V; Lyons JM; Hudson CL; Struble SL; Hakimi M
J Heart Valve Dis; 1997 Jul; 6(4):335-42. PubMed ID: 9263860
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts.
Lopez-Cepero M; Sanders CE; Buggs J; Bowers V
Transplantation; 2002 Mar; 73(5):817-9. PubMed ID: 11907435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
